4.3 Article

Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic steatohepatitis

期刊

CLINICS IN LIVER DISEASE
卷 22, 期 1, 页码 23-+

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2017.08.007

关键词

Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Inflammation; Fibrosis; Genetic factors

资金

  1. Allergan
  2. Galectin
  3. Gilead
  4. Immuron
  5. Intercept
  6. NGM Biopharma

向作者/读者索取更多资源

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH) and ultimately may lead to cirrhosis. Hepatic steatosis or fatty liver is defined as increased accumulation of lipids in hepatocytes and results from increased production or reduced clearance of hepatic triglycerides or fatty acids. Fatty liver can progress to NASH in a significant proportion of subjects. NASH is a necroinflammatory liver disease governed by multiple pathways that are not completely elucidated. This article describes the main mechanisms that have been reported to contribute to the pathophysiology of NAFLD and NASH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据